About the Company
Regulus Therapeutics Inc. or Regulus (Nasdaq: RGLS) is a clinical stage biopharmaceutical company focused on the development of first-in-class drugs that target microRNAs to treat a broad range of diseases. Regulus was established in September 2007 by Alnylam Pharmaceuticals and Isis Pharmaceuticals.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $RGLS News
Regulus: It Is Finding Its Stride Despite Initial Setback In Targeting ADPKD
Regulus Therapeutics Inc. had promising results in a phase 1b study for ADPKD patients using RGLS8429, potential accelerated ...
RGLS Regulus Therapeutics Inc.
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States.
Regulus Therapeutics (NASDAQ: RGLS)
Regulus Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and ...
Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates
SAN DIEGO, March 21, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs ...
Regulus Therapeutics Inc (RGLS) Reports Year-End Earnings, Highlights Key Clinical Advancements
Warning! GuruFocus has detected 4 Warning Signs with RGLS. On March 21, 2024, Regulus Therapeutics Inc (NASDAQ:RGLS) released its 8-K filing, detailing its financial results for the fourth quarter ...
Buy Rating Reaffirmed for Regulus Therapeutics Amid Promising Drug Development Milestones
Begin your TipRanks Premium journey today. Regulus (RGLS) Company Description: Regulus Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of drugs ...
Regulus Therapeutics Stock (NASDAQ:RGLS), Analyst Ratings, Price Targets, Predictions
Regulus Therapeutics Inc has a consensus price target of $5.5, established from looking at the 16 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co ...
Regulus: Q4 Earnings Snapshot
SAN DIEGO (AP) — SAN DIEGO (AP) — Regulus Therapeutics Inc. (RGLS) on Thursday reported a loss of $8.1 million in its fourth quarter. The San Diego-based company said it had a loss of 40 cents ...
Regulus Therapeutics Inc.
Regulus Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and ...
Regulus Therapeutics Inc.: Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates
Regulus Therapeutics Inc. (Nasdaq: RGLS) is a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its ...
Regulus Therapeutics Inc RGLS
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Regulus Therapeutics Inc RGLS
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Loading the latest forecasts...